Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. [electronic resource]
Producer: 20091027Description: 2764-73 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Azacitidine -- administration & dosage
- Benzamides -- administration & dosage
- Cytogenetic Analysis
- DNA Damage -- drug effects
- Drug Administration Schedule
- Epigenesis, Genetic -- drug effects
- Female
- Hematologic Neoplasms -- diagnosis
- Humans
- Male
- Middle Aged
- Prognosis
- Pyridines -- administration & dosage
- Time Factors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.